Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY22 results · Apr–Jun 2021
Solara Active Pharma Sciences reported revenue from operations of ₹405.57 crore (up 16.4% from Q1 FY21) and net profit of ₹50.11 crore (up 18.5% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 405.57 | 348.42 | +16.4% | 444.21 | −8.7% |
| Other income | 5.91 | 4.58 | +29.0% | 9.78 | −39.6% |
| Total income | 411.48 | 353.00 | +16.6% | 453.99 | −9.4% |
| Profit before tax | 50.11 | 42.32 | +18.4% | 56.62 | −11.5% |
| Net profit for the period | 50.11 | 42.27 | +18.5% | 56.61 | −11.5% |
| Attributable to shareholders of the company | 50.07 | 42.28 | +18.4% | 56.65 | −11.6% |
| EPS, basic (₹) | 13.95 | 15.74 | −11.4% | 15.57 | −10.4% |
| Net margin (%) | 12.4 | 12.1 | 12.7 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 405.57 | 348.42 | +16.4% | 444.21 | −8.7% |
| Other income | 5.80 | 4.58 | +26.6% | 9.86 | −41.2% |
| Total income | 411.37 | 353.00 | +16.5% | 454.07 | −9.4% |
| Profit before tax | 50.56 | 42.09 | +20.1% | 57.15 | −11.5% |
| Net profit for the period | 50.56 | 42.09 | +20.1% | 57.15 | −11.5% |
| EPS, basic (₹) | 14.07 | 15.67 | −10.2% | 15.47 | −9.0% |
| Net margin (%) | 12.5 | 12.1 | 12.9 |
Consolidated
- Filed with BSE
- 05 Aug 2021, 13:56 IST
- Board meeting
- 04 Aug 2022
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2021, 13:56 IST
- Board meeting
- 04 Aug 2022
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE